Figure 1 Initial management of a patient with acute heart failure

Slides:

Advertisements

Similar presentations

B-type natriuretic peptide in paediatric patients with congenital heart disease by Andreas Koch, Stefan Zink, and Helmut Singer EHJ Volume 27(7):

Advertisements

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE PATIENT QUALITY OF LIFE STATISTICS.

Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.

Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Nat. Rev. Cardiol. doi: /nrcardio

Heart - Pathophysiology

Algorithm for the management of aortic valve stenosis

Nat. Rev. Cardiol. doi: /nrcardio

Event Rates for Commonly Performed Cardiovascular Procedures

Figure 1 Diagnostic flowchart for patients with suspected heart failure—showing alternative ‘echocardiography first’ (blue) or ‘natriuretic peptide first’

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 10 Assessment of myocardial fibrosis

Nat. Rev. Cardiol. doi: /nrcardio

Reproduced with permission from Yancy, C. W. et al. 2017

Diabetes Mellitus and Heart Failure

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 7 European Society of Cardiology 2016

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Results of diastolic stress testing

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 The depolarization theory of Brugada syndrome

Figure 10 The energy depletion hypothesis

Figure 1 Decision tree integrating the assessment,

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Date of download: 2/22/2017 © The European Society of Cardiology All rights reserved. For permissions please

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Absolute difference in seasonal peak

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

Figure 6 The haemodynamic effects of

Nat. Rev. Cardiol. doi: /nrcardio

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Editorial Heart Failure Clinics

Nat. Rev. Cardiol. doi: /nrcardio

Figure 9 Management of atrial fibrillation

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Kaplan–Meier survival curves for outcomes among chronic obstructive pulmonary disease (COPD) patients without obstructive sleep apnoea (OSA) (COPD group),

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Rick A. Nishimura et al. JACC 2017;70:

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

Khalid Abd El Hady Compiled by Soheir Mahfouz

Presentation transcript:

Figure 1 Initial management of a patient with acute heart failure Figure 1 | Initial management of a patient with acute heart failure. Algorithm for the management of patients with acute heart failure (AHF). *Acute mechanical cause refers to myocardial rupture complicating acute coronary syndrome (free wall rupture, ventricular septal defect, or acute mitral regurgitation); chest trauma or cardiac intervention; acute native or prosthetic valve incompetence secondary to endocarditis; aortic dissection; or thrombosis. AHF, acute heart failure; BiPAP, bilevel positive airway pressure; CCU, coronary care unit; CPAP, continuous positive airway pressure; ICU, intensive care unit. Modified from Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehw128 (2016), with permission from Oxford University Press and the ESC. Modified from Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehw128 (2016), with permission from Oxford University Press and the ESC Jessup, M. et al. (2016) 2016 ESC and ACC/AHA/HFSA heart failure guideline update — what is new and why is it important? Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.134